Dig Liver Dis:高体重指数和饮酒对肝癌相关死亡率影响

2020-03-14 MedSci原创 MedSci原创

目前已知高体重指数(BMI)和饮酒是肝癌的明确危险因素。本项研究的目的是在全球和国家层面描述高BMI和酒精摄入对肝癌相关死亡的影响。

背景:目前已知高体重指数(BMI)和饮酒是肝癌的明确危险因素。本项研究的目的是在全球和国家层面描述高BMI和酒精摄入对肝癌相关死亡的影响。

方法:高BMI和饮酒的肝癌相关死亡率数据是从全球疾病负担数据库中收集的。研究人员估计的平均百分比变化用于量化肝癌年龄标准化死亡率(ASMR)趋势。

结果:2017年,全球约有819435例与肝癌相关的死亡。在研究期间,整体ASMR从每100000的4.42增加到每100000的5.17。在全球和大多数国家,归因于高BMI的肝癌ASMR持续增加。在研究期间,与酒精使用相关的肝癌死亡率每年降低0.17%。

结论:高BMI相关肝癌死亡率的增加表明目前我们对超重的关注很少,应该加以重视。

原始出处:

Guoyao Zhang. Et al. Contribution of high body mass index and alcohol use to liver cancer-related mortality: A study based on 195 countries or territories. Digestive and Liver Disease. 2020.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2013208, encodeId=ab0b2013208a8, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Oct 23 09:23:05 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=380503, encodeId=b02638050340, content=文医刊编论, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/sL9VBZ1wX08pLbnNXBTnGAPaat7fkRukxXNMYNK4LzUWFibcvg7WRPme5Uy5mh1f5HW9qicG1etmDBGsqsrbg2yg/132, createdBy=9ce65310990, createdName=xcdnxj, createdTime=Sun Mar 15 14:48:02 CST 2020, time=2020-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040266, encodeId=570610402668e, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Sun Mar 15 02:23:05 CST 2020, time=2020-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=380476, encodeId=0ff83804e675, content=學習了,很有用,不錯, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Sun Mar 15 00:14:13 CST 2020, time=2020-03-15, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2013208, encodeId=ab0b2013208a8, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Oct 23 09:23:05 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=380503, encodeId=b02638050340, content=文医刊编论, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/sL9VBZ1wX08pLbnNXBTnGAPaat7fkRukxXNMYNK4LzUWFibcvg7WRPme5Uy5mh1f5HW9qicG1etmDBGsqsrbg2yg/132, createdBy=9ce65310990, createdName=xcdnxj, createdTime=Sun Mar 15 14:48:02 CST 2020, time=2020-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040266, encodeId=570610402668e, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Sun Mar 15 02:23:05 CST 2020, time=2020-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=380476, encodeId=0ff83804e675, content=學習了,很有用,不錯, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Sun Mar 15 00:14:13 CST 2020, time=2020-03-15, status=1, ipAttribution=)]
    2020-03-15 xcdnxj

    文医刊编论

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2013208, encodeId=ab0b2013208a8, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Oct 23 09:23:05 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=380503, encodeId=b02638050340, content=文医刊编论, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/sL9VBZ1wX08pLbnNXBTnGAPaat7fkRukxXNMYNK4LzUWFibcvg7WRPme5Uy5mh1f5HW9qicG1etmDBGsqsrbg2yg/132, createdBy=9ce65310990, createdName=xcdnxj, createdTime=Sun Mar 15 14:48:02 CST 2020, time=2020-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040266, encodeId=570610402668e, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Sun Mar 15 02:23:05 CST 2020, time=2020-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=380476, encodeId=0ff83804e675, content=學習了,很有用,不錯, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Sun Mar 15 00:14:13 CST 2020, time=2020-03-15, status=1, ipAttribution=)]
    2020-03-15 留走人康

    肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2013208, encodeId=ab0b2013208a8, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Oct 23 09:23:05 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=380503, encodeId=b02638050340, content=文医刊编论, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/sL9VBZ1wX08pLbnNXBTnGAPaat7fkRukxXNMYNK4LzUWFibcvg7WRPme5Uy5mh1f5HW9qicG1etmDBGsqsrbg2yg/132, createdBy=9ce65310990, createdName=xcdnxj, createdTime=Sun Mar 15 14:48:02 CST 2020, time=2020-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040266, encodeId=570610402668e, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Sun Mar 15 02:23:05 CST 2020, time=2020-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=380476, encodeId=0ff83804e675, content=學習了,很有用,不錯, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Sun Mar 15 00:14:13 CST 2020, time=2020-03-15, status=1, ipAttribution=)]
    2020-03-15 飛歌

    學習了,很有用,不錯

    0

相关资讯

Cell Death Dis:低氧通过HIF/HEY1/PINK1通路调节肝癌细胞的线粒体活性

缺氧在癌症中很常见。缺氧,由于缺乏氧气(O2)作为电子受体,导致通过线粒体电子传输链的电子转移效率低下,导致活性氧(ROS)积累,从而可能造成不可逆的细胞损伤。通过可引发各种分子事件的缺氧诱导因子1(HIF-1),细胞能够克服低氧。有关由HIF-1调控的新分子机制的知识对于针对缺氧肿瘤的新治疗干预非常重要。研究人员通过肝细胞癌(HCC)模型,发现HIF-1和Notch信号通路通过交叉作用来控制癌细

Lancet oncol:PD-1抑制剂Camrelizumab治疗晚期肝癌患者的疗效和安全性

阻断PD-1与其配体的相互作用是治疗晚期肝癌的一种有希望的治疗策略。本研究旨在评估抗PD-1抑制剂camrelizumab在既往治疗过的晚期肝癌患者中的抗肿瘤活性和安全性。本研究是一个在中国的13个研究中心开展的多中心的开放性的平行组的随机化2期试验,招募年满18岁的病理确诊的、既往系统治疗后进展的或不能耐受的晚期肝癌患者。将受试患者随机(1:1)分至两组,分别2周或3周接受一次camrelizu

肝癌椎管内硬脊膜外转移1例

男,43岁,因胸背部持续性刺痛2个月加重10 d,伴双下肢无力、麻木逐渐加重、大小便功能障碍5 d入院。既往肺结核病史20年,乙型病毒性肝炎病史10年。入院前10 d当地县医院肺部CT检查示双肺上叶、右肺下叶陈旧性结核;胸8椎体水平椎管内异常稍高密度影。

Lancet Gastroen Hepatol:131I-西妥昔单抗辅助治疗改善肝癌切除患者预后

肝切除术后有效辅助治疗是肝细胞癌(HCC)是一个重要的研究领域。放射性碘( 131I)标记的西妥昔单抗针对HCC高表达的CD147 (又名 basigin 或 HAb18G)抗原的放射性单克隆抗体。近

华海清:2019年肝癌内科治疗进展

2019年是不平凡的一年,我们的心情跌宕起伏,肝癌免疫治疗的意外失利令我们困惑迷茫,而联合治疗的突出效果又使我们心潮彭拜,欢欣鼓舞,这一年定会在肝癌的治疗史上绘上浓浓的一笔。 1、PD-1单抗在肝细胞癌(HCC)一、二线治疗中折戟沉沙 纳武单抗(Nivolumab,简称NIVO) 一线治疗HCC出师不利 纳武单抗是PD-1免疫检查点抑制剂,一项I/Ⅱ期的临床研究(CheckMa

Hepatol Int:乙型肝炎治疗患者肝癌发生风险:替诺福韦低于恩替卡韦

富马酸替诺福韦(TDF)在降低乙型肝炎患者肝细胞癌发生风险上是否优于恩替卡韦(ETV)目前仍存在争议。本研究拟从临床医学和方法学两方面的角度,通过荟萃分析来探讨这一问题。